The Motley Fool
31 Oct 2026, 22:10 UTC · 2h ago
After Eli Lilly's Explosive Earnings Report, Is It Too Late to Buy the Stock?
Impact · against what's priced in
Eli Lilly's explosive Q3 results and guidance lift are largely non-catalysts as the current price already incorporates aggressive revenue targets and GLP-1 dominance. Novo Nordisk remains a strong grower, but its loss of U.S. market share to Lilly is a persistent headwind.
- LLY+0.00
Already priced in
- The price assumes
Revenue guidance of $85–87 billion for 2026
The reported 39% revenue increase to $24 billion and the lifted full-year forecast align with the growth trajectory the market already assumes for 2026.
What LLY's price assumes · Sep 10
